Disposition of artesunate and dihydroartemisinin after administration of artesunate suppositories in children from Papua New Guinea with uncomplicated malaria.
A detailed pharmacokinetic analysis was performed with 47 children from Papua New Guinea with uncomplicated falciparum or vivax malaria treated with artesunate (ARTS) suppositories (Rectocaps) given in two doses of approximately 13 mg/kg of body weight 12 h apart. Following an intensive sampling protocol, samples were assayed for ARTS and its primary active metabolite, dihydroartemisinin (DHA), by liquid chromatography-mass spectrometry. A population pharmacokinetic model was developed to describe the data. Following administration of the first dose, the mean maximal concentrations of ARTS and DHA were 1,085 nmol/liter at 0.9 h and 2,525 nmol/liter at 2.3 h, respectively. The absorption half-life for ARTS was 2.3 h, and the conversion half-life (ARTS to DHA) was 0.27 h, while the elimination half-life of DHA was 0.71 h. The mean common volumes of distribution for ARTS and DHA relative to bioavailability were 42.8 and 2.04 liters/kg, respectively, and the mean clearance values relative to bioavailability were 6 and 2.2 liters/h/kg for ARTS and DHA, respectively. Substantial interpatient variability was observed, and the bioavailability of the second dose relative to that of the first was estimated to be 0.72. The covariates age, sex, and alpha-thalassemia genotype were not influential in the pharmacokinetic model development; but the inclusion of weight as a covariate significantly improved the performance of the model. An ARTS suppositories dose of 10 of 20 mg/kg is appropriate for use in children with uncomplicated malaria.
Karunajeewa
Harin A
HA
School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia.
Ilett
Kenneth F
KF
Dufall
Kitiya
K
Kemiki
Adedayo
A
Bockarie
Moses
M
Alpers
Michael P
MP
Barrett
P Hugh
PH
Vicini
Paolo
P
Davis
Timothy M E
TM
D000375:Aging / Q000502:physiology; D000962:Antimalarials / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D037621:Artemisinins / Q000008:administration & dosage / Q000378:metabolism* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000077332:Artesunate; D001835:Body Weight / Q000502:physiology; D002648:Child; D002851:Chromatography, High Pressure Liquid; D005260:Female; D005838:Genotype; D006207:Half-Life; D006801:Humans; D008288:Malaria / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D015233:Models, Statistical; D010219:Papua New Guinea; D011153:Population; D012717:Sesquiterpenes / Q000008:administration & dosage / Q000378:metabolism* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D012727:Sex Characteristics; D021241:Spectrometry, Mass, Electrospray Ionization; D013488:Suppositories; D014018:Tissue Distribution; D017085:alpha-Thalassemia / Q000150:complications / Q000235:genetics
D000962:Antimalarials; D037621:Artemisinins; D012717:Sesquiterpenes; D013488:Suppositories; D000077332:Artesunate; C039060:artenimol